IL165016A - Composition for use in the induction of antigen specific immunologic tolerance, a kit comprising same and use thereof - Google Patents

Composition for use in the induction of antigen specific immunologic tolerance, a kit comprising same and use thereof

Info

Publication number
IL165016A
IL165016A IL165016A IL16501604A IL165016A IL 165016 A IL165016 A IL 165016A IL 165016 A IL165016 A IL 165016A IL 16501604 A IL16501604 A IL 16501604A IL 165016 A IL165016 A IL 165016A
Authority
IL
Israel
Prior art keywords
kit
induction
composition
same
antigen specific
Prior art date
Application number
IL165016A
Other versions
IL165016A0 (en
Original Assignee
Biomarin Pharm Inc
Los Angeles Biomed Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomarin Pharm Inc, Los Angeles Biomed Res Inst filed Critical Biomarin Pharm Inc
Publication of IL165016A0 publication Critical patent/IL165016A0/en
Publication of IL165016A publication Critical patent/IL165016A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A61K38/095—Oxytocins; Vasopressins; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL165016A 2002-05-06 2004-11-03 Composition for use in the induction of antigen specific immunologic tolerance, a kit comprising same and use thereof IL165016A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/141,668 US7485314B2 (en) 2002-05-06 2002-05-06 Induction of antigen specific immunologic tolerance
PCT/US2003/013843 WO2003094840A2 (en) 2002-05-06 2003-05-05 Induction of antigen specific immunologic tolerance

Publications (2)

Publication Number Publication Date
IL165016A0 IL165016A0 (en) 2005-12-18
IL165016A true IL165016A (en) 2012-01-31

Family

ID=29399718

Family Applications (1)

Application Number Title Priority Date Filing Date
IL165016A IL165016A (en) 2002-05-06 2004-11-03 Composition for use in the induction of antigen specific immunologic tolerance, a kit comprising same and use thereof

Country Status (16)

Country Link
US (3) US7485314B2 (en)
EP (1) EP1507555B1 (en)
JP (1) JP4933042B2 (en)
CN (1) CN100360182C (en)
AR (1) AR039882A1 (en)
AU (1) AU2003228829B2 (en)
BR (1) BR0309809A (en)
CA (1) CA2492394A1 (en)
ES (1) ES2401681T3 (en)
HK (1) HK1081438A1 (en)
IL (1) IL165016A (en)
MX (1) MXPA04009292A (en)
TW (1) TWI349556B (en)
UY (1) UY27795A1 (en)
WO (1) WO2003094840A2 (en)
ZA (1) ZA200409787B (en)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7629309B2 (en) 2002-05-29 2009-12-08 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
WO2003020039A1 (en) * 2001-08-28 2003-03-13 Rush-Presbyterian-St. Luke's Medical Center Immune tolerance to predetermined antigens
JP4563171B2 (en) * 2002-05-24 2010-10-13 シェーリング コーポレイション Neutralizing human anti-IGFR antibody
WO2005002515A2 (en) 2003-06-20 2005-01-13 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US20050026823A1 (en) * 2003-06-20 2005-02-03 Biomarin Pharmaceutical Inc. Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
US7442372B2 (en) 2003-08-29 2008-10-28 Biomarin Pharmaceutical Inc. Delivery of therapeutic compounds to the brain and other tissues
US7326567B2 (en) 2003-11-12 2008-02-05 Schering Corporation Plasmid system for multigene expression
AR046639A1 (en) * 2003-11-21 2005-12-14 Schering Corp ANTI-IGFR1 ANTIBODY THERAPEUTIC COMBINATIONS
JP2008521907A (en) * 2004-12-03 2008-06-26 シェーリング コーポレイション Biomarkers for preselecting patients for anti-IGF1R treatment
JP2008528043A (en) * 2005-02-04 2008-07-31 ダウ・アグロサイエンシーズ・エルエルシー Anti-T cell and autoantigen therapy for autoimmune diseases
BRPI0608777A2 (en) * 2005-04-15 2010-01-26 Schering Corp methods for treating or preventing cancer, as well as use of igf1r inhibitors in the preparation of pharmaceutical compositions
NZ564098A (en) * 2005-06-15 2010-04-30 Schering Corp Anti-IGF1R antibody formulations
JP2009508494A (en) 2005-09-16 2009-03-05 ラプトール ファーマシューティカル インコーポレイテッド Compositions comprising receptor-binding protein (RAP) variants specific for proteins comprising CR and uses thereof
WO2008125903A2 (en) * 2006-12-12 2008-10-23 Chaim Sheba Medical Center Method of inhibiting an undesired immune response
KR101801454B1 (en) * 2007-03-21 2017-11-24 랩터 파마슈티컬스 인코포레이티드 Cyclic receptor-associated protein(rap) peptides
EP2279210B1 (en) 2008-05-07 2017-04-12 BioMarin Pharmaceutical Inc. Lysosomal targeting peptides and uses thereof
EP2475376B1 (en) 2009-06-17 2016-03-30 BioMarin Pharmaceutical Inc. Formulations for lysosomal enzymes
AU2010311515B2 (en) * 2009-10-27 2014-02-20 Erytech Pharma Composition to induce specific immune tolerance
EP3260132B1 (en) * 2010-10-27 2022-02-09 Takeda Pharmaceutical Company Limited Fviii peptides for immune tolerance induction and immunodiagnostics
CA2834619A1 (en) 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Controlled release of immunosuppressants from synthetic nanocarriers
BR112013029501A2 (en) * 2011-05-16 2017-01-24 Genzyme Corp induction of immune tolerance using methotrexate
ES2899848T3 (en) 2012-01-12 2022-03-15 Bioverativ Therapeutics Inc Reduced immunogenicity against factor VIII in individuals undergoing factor VIII therapy
EP2833913A1 (en) * 2012-04-02 2015-02-11 University Of Bristol Tolerisation- inducing composition
CN106668852B (en) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 Composition for treating and/or preventing type I diabetes and application thereof
TWI711632B (en) 2012-11-27 2020-12-01 美商拜奧馬林製藥公司 Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
JP6580558B2 (en) 2013-05-03 2019-09-25 セレクタ バイオサイエンシーズ インコーポレーテッドＳｅｌｅｃｔａ Ｂｉｏｓｃｉｅｎｃｅｓ，Ｉｎｃ． Methods and compositions for enhancing CD4 + regulatory T cells
CN105377039A (en) * 2013-05-15 2016-03-02 明尼苏达大学董事会 Adeno-associated virus mediated gene transfer to the central nervous system
US10046064B2 (en) 2014-09-07 2018-08-14 Selecta Biosciences, Inc. Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses
EP3344575B1 (en) 2015-09-04 2020-04-15 SQZ Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
US11262348B2 (en) 2015-11-06 2022-03-01 Biomarin Pharmaceutical Inc. Cell-based assays for detection of antibodies or other factors that neutralize uptake of lysosomal enzymes
EP3452104A1 (en) 2016-04-15 2019-03-13 The Trustees of The University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
EP3592389A1 (en) 2017-03-11 2020-01-15 Selecta Biosciences, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
CA3104797A1 (en) * 2018-06-22 2019-12-26 Junten Bio Co., Ltd. Antibody capable of inducing immune tolerance produced using cell mixture having complexed state, and induced lymphocyte or cell therapeutic agent and cell therapy method each using induced lymphocyte
CN113301925A (en) 2018-12-19 2021-08-24 小利兰·斯坦福大学理事会 Bifunctional molecules for lysosomal targeting and related compositions and methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4117118A (en) 1976-04-09 1978-09-26 Sandoz Ltd. Organic compounds
US5135915A (en) * 1988-10-14 1992-08-04 Genentech, Inc. Method for the treatment of grafts prior to transplantation using TGF-.beta.
ATE304050T1 (en) 1991-02-22 2005-09-15 Inst Medical W & E Hall HBGAD AND HIGAD POLYPEPTIDES AND NUCLEIC ACIDS AND THEIR USE IN THE DIAGNOSIS AND TREATMENT OF GAD AUTOANTIGEN-ASSOCIATED DISEASES
US6149909A (en) 1995-06-23 2000-11-21 Women's And Children's Hospital Synthetic α-L-iduronidase and genetic sequences encoding same
ATE193208T1 (en) * 1992-02-10 2000-06-15 Univ Duke USE OF SYNTHETIC PEPTIDES TO INDUCE TOLERANCE TO T AND B CELL EPITOPES OF AUTOANTIGENS
US5747034A (en) 1992-07-09 1998-05-05 Chiron Corporation Methods and materials for the induction of T cell anergy
US5597563A (en) * 1992-09-04 1997-01-28 Beschorner; William E. Method induction of antigen-specific immune tolerance
CA2211993A1 (en) * 1995-01-31 1996-08-08 The Rockefeller University Identification of dec, (dentritic and epithelial cells, 205 kda), a receptor with c-type lectin domains, nucleic acids encoding dec, and uses thereof
JP2001511187A (en) 1997-02-28 2001-08-07 エンゾー セラピュウティクス， インコーポレイテッド Novel process for selective immune down-regulation (SIDR)
US6426208B1 (en) * 1999-11-12 2002-07-30 Harbor-Ucla Research And Education Institute Recombinant α-L-iduronidase, methods for producing and purifying the same and methods for treating diseases caused by deficiencies thereof
US20020014242A1 (en) * 2000-07-31 2002-02-07 Abraham Scaria Use of rapamycin to inhibit immune response and induce tolerance to gene therapy vector and encoded transgene products
US20050191309A1 (en) * 2002-05-06 2005-09-01 Kakkis Emil D. Induction of antigen specific immunologic tolerance

Also Published As

Publication number Publication date
JP4933042B2 (en) 2012-05-16
MXPA04009292A (en) 2005-06-08
WO2003094840A2 (en) 2003-11-20
ZA200409787B (en) 2006-07-26
US20040009906A1 (en) 2004-01-15
EP1507555B1 (en) 2012-12-19
TW200400045A (en) 2004-01-01
AU2003228829A1 (en) 2003-11-11
US20090238818A1 (en) 2009-09-24
US20030211113A1 (en) 2003-11-13
CN1652814A (en) 2005-08-10
EP1507555A2 (en) 2005-02-23
CA2492394A1 (en) 2003-11-20
CN100360182C (en) 2008-01-09
BR0309809A (en) 2007-01-09
WO2003094840A3 (en) 2004-03-11
ES2401681T3 (en) 2013-04-23
EP1507555A4 (en) 2009-07-15
AU2003228829B2 (en) 2009-05-21
AR039882A1 (en) 2005-03-09
US7485314B2 (en) 2009-02-03
HK1081438A1 (en) 2006-05-19
US7883707B2 (en) 2011-02-08
TWI349556B (en) 2011-10-01
JP2005530762A (en) 2005-10-13
IL165016A0 (en) 2005-12-18
UY27795A1 (en) 2003-11-28

Similar Documents

Publication Publication Date Title
IL165016A (en) Composition for use in the induction of antigen specific immunologic tolerance, a kit comprising same and use thereof
IL225633A0 (en) Anti-alpha-v-beta - 6 antibodies and uses thereof
EP1551447A4 (en) Anti-addl antibodies and uses thereof
AU2003299778A8 (en) Antibodies against gpr64 and uses thereof
AU2003220205A8 (en) Ethanol-diesel fuel composition and methods thereof
EP1539941A4 (en) Adzymes and uses thereof
EP1469860A4 (en) Anti-cancer combination and use thereof
EP1699485A4 (en) Anti-hydroxylase antibodies and uses thereof
HK1045826A1 (en) Fittings for use in files
IL172510A0 (en) Antibodies and uses thereof
EP1589033A4 (en) Antibody and use thereof
IL166063A0 (en) Antibodies and uses thereof
AU2003249533A8 (en) Neoplasm specific antibodies and uses thereof
AU2003231827A8 (en) Pseudo-tissues and uses thereof
AU2003298739A8 (en) Intermedin and its uses
AU2003228355A8 (en) Adipocytes and uses thereof
EP1541677A4 (en) Novel proteins and use thereof
EP1577322A4 (en) Novel proteins and use thereof
EP1627888A4 (en) Antibody and use thereof
AU2003216442A8 (en) Enkurin and uses thereof
AU2003256572A8 (en) Negative selections assays, and compositions thereof
GB0116220D0 (en) Improvements in fasteners
GB0114432D0 (en) Improvements in fasteners
GB0227080D0 (en) Antibodies and uses thereof
GB0218253D0 (en) Novel composition and use

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees